MYSTERIOUS: Hrmy - What They Never Told You

Top 3 Health Care Stocks That Are Preparing To Pump In Q4

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga · Oct 6, 2025

Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) released topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS).

Benzinga · Sep 24, 2025

3 Emerging Biotech Firms Pioneering Next-Gen Therapies

The biotech industry is on a stable growth path, owing to the integration of modern technologies and rapid drug discoveries. Thus, investing in fundamentally stable biotech stocks, Veracyte (VCYT), Amicus Therapeutics (FOLD), and Harmony Biosciences (HRMY), could be one way to capitalize on the industry's prospects. Read more….

StockNews.com · Feb 18, 2025

Undervalued Biotech Stocks Ready for a Breakout

The biotech industry's future appears bright due to advancements in biochemical and pharma technologies, AI integration, rising targeted treatments, and increased R&D spending driving breakthroughs. Therefore, it could be wise to invest in undervalued biotech stocks such as Harmony Biosciences Holdings (HRMY), United Therapeutics (UTHR), and BioMarin Pharmaceutical (BMRN). Read…

StockNews.com · Sep 9, 2024

3 Value Biotech Stocks With Breakout Potential in 2024

Given growing healthcare spending, supportive government policies, and technological innovation, the biotechnology industry is poised for solid long-term growth. Thus, investors could consider buying quality biotech stocks Harmony Biosciences (HRMY), Esperion Therapeutics (ESPR), and Entrada Therapeutics (TRDA), which are trading at a discount. Read on….

StockNews.com · May 28, 2024

3 Biotech Stocks to Monitor for May Moves

The biotech industry is well poised to flourish, buoyed by its strong emphasis on technology-driven advancements to address complex medical challenges and government funding. Hence, quality biotech stocks Harmony Biosciences Holdings (HRMY), Illumina (ILMN), and Compugen (CGEN) could be ideal watchlist additions for May. Read more….

StockNews.com · May 14, 2024

3 Biotech Stocks to Buy to Power Through April

The biotech sector is primed for growth, fueled by a surge in FDA approvals, anticipated M&A deals, and the integration of AI in drug discovery. So, fundamentally sound biotech stocks Theratechnologies (THTX), Harmony Biosciences (HRMY), and Shionogi & Co. (SGIOY) might be solid buys in this month. Keep reading.

StockNews.com · Apr 18, 2024

3 Biotech Stocks to Buy in 2024

The biotech industry is expected to grow rapidly due to rising demand for tailored treatments, increased R&D spending, and technological advancements. Therefore, fundamentally strong biotech stocks Harmony Biosciences Holdings (HRMY), Illumina (ILMN), and Halozyme Therapeutics (HALO) could be worth adding to your portfolio. Read on.

StockNews.com · Apr 9, 2024

3 B-Rated Biotech Stocks to Boost Your Bottom Line

The biotech industry’s growth prospects look promising due to innovative drugs and therapies, government initiatives, and technological advancements. Therefore, investors could consider buying fundamentally strong biotech stocks BioMarin Pharmaceutical (BMRN), Illumina (ILMN), and Harmony Biosciences (HRMY). These stocks are B-rated (Buy) in our proprietary rating system. Read on.

StockNews.com · Mar 15, 2024

4 Biotech Stocks With Massive Buy Potential

The biotech sector is poised for robust long-term growth, driven by significant developments in drug approvals, innovative therapies, and government-backed initiatives. Hence, investors might consider buying fundamentally solid biotech stocks ProQR Therapeutics (PRQR), Foghorn Therapeutics (FHTX), Harmony Biosciences (HRMY), and Organogenesis Holdings (ORGO) with massive buy potential. Keep reading.

StockNews.com · Jan 30, 2024